Literature DB >> 7139062

Excretion of digoxin and its metabolites in urine after a single oral dose in healthy subjects.

J O Magnusson, B Bergdahl, C Bogentoft, U E Jonsson, L Tekenbergs.   

Abstract

The 3-day urinary excretion of digoxin, its conjugated and unconjugated hydrolytic metabolites and dihydrodigoxin, was studied in 8 healthy men after oral administration of tritiated digoxin. Analysis was performed by high pressure liquid chromatography (HPLC). The total radioactivity corresponded to 45.4 +/- 2.0 per cent (mean +/- S.E.M.) of the dose. By HPLC 42.4 +/- 2.7 per cent was recovered before and 44.0 +/- 2.7 per cent after deconjugation of the samples. Digoxin and dihydrodigoxin constituted 40.3 +/- 2.9 per cent; of this 0.7 +/- 0.4 per cent was dihydrodigoxin. The sum of the hydrolytic metabolites was 2.1 +/- 0.3 per cent before and 3.4 +/- 0.5 per cent after deconjugation. No correlation was found between gastric pH and the production of hydrolytic metabolites. The relative amount of these metabolites was maximal (mean 13.4 per cent of the excretion) in the 4-8 h sampling period. During the first 8 h an average of 8.6 per cent of the radioactivity was not recovered by HPLC. The metabolism of digoxin as judged by urinary excretion was limited and showed great variation during the early hours after treatment. The excretion of unchanged digoxin in some individuals constituted as little as 60 per cent over the first 12 h after dosing.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7139062     DOI: 10.1002/bdd.2510030304

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  5 in total

1.  Fasting and postprandial absorption of digoxin from a microencapsulated formulation.

Authors:  B Bergdahl; C Bogentoft; U E Jonsson; J O Magnusson
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

2.  Metabolism of digoxin after oral and intrajejunal administration.

Authors:  J O Magnusson
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

3.  The bioavailability of digoxin from three oral formulations measured by a specific h.p.l.c. assay.

Authors:  A F Cohen; R Kroon; H C Schoemaker; D D Breimer; A Van Vliet-Verbeek; H C Brandenburg
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

4.  Inhibition by basic drugs of digoxin secretion into human bile.

Authors:  A Hedman
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

5.  Increased metabolism to dihydrodigoxin after intake of a microencapsulated formulation of digoxin.

Authors:  J O Magnusson; B Bergdahl; C Bogentoft; S Gustafsson; U E Jonsson
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.